Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.15 - $43.40
Previous Close$40.87
Volume1.01M
Average Volume (3M)663.66K
Market Cap
$3.11B
Enterprise Value$2.41B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$395.50M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 07, 2024EPS Estimate
-$1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.32
Shares Outstanding76,924,170
10 Day Avg. Volume689,101
30 Day Avg. Volume663,660
Standard Deviation0.14
R-Squared0.06
Alpha0.00170
Financial Highlights & Ratios
Price to Book (P/B)-3.39
Price to Sales (P/S)3.49
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda-12.70
Forecast
1Y Price Target
$41.08Price Target Upside-4.86% Downside
Rating ConsensusHold
Number of Analyst Covering15
PTC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market PotentialThere are no approved therapies for pediatric patients with FA, suggesting a potential market opportunity.
Pipeline OpportunitiesPTC has several late-stage pipeline catalysts coming that provide attractive risk/reward for the stock.
Regulatory ProgressPTC management is highly confident the NDA will be accepted for review following pre-NDA feedback from FDA.
Bears Say
Clinical Trial ResultsPhase 3 MOVE-FA trial for vatiquinone failed to meet its primary endpoint of mFARS benefit at 72 weeks in the primary analysis population.
Financial PerformancePTC Therapeutics' expected share price return is projected to be negative.
Regulatory ChallengesThe ongoing regulatory challenges and delays with Translarna in both the EU and US markets continue to pose significant hurdles for PTCT.
---
Ownership Overview
1.15% Insiders
30.12% Mutual Funds
1.02% Other Institutional Investors
50.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $18.15 and its highest was $43.40 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is 2 days ago.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Aug 08, 2024. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.17.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Overvalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$1.52.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 76,924,170 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.29 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went down -3.575%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 33M.
---
PTC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.08 (-4.86% Downside)
$41.08 (-4.86% Downside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 11.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.21%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q2 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$41.08
▼(-4.86% Downside)
Technical Analysis
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+34.97%
assigned a buy rating last month
Copying Joel Beatty's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +34.97% per trade.
---